Osborn Williams & Donohoe’s Teva Pharmaceuticals TEVA Stock Holding History

Osborn Williams & Donohoe’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-33,868	Closed	-$233K	–	313
2019 Q3	$233K	Hold	33,868	–	–	0.02%	291
2019 Q2	$313K	Buy	33,868 +4,423	+15%	+$53.3K	0.03%	267
2019 Q1	$427K	Buy	29,445 +8,545	+41%	+$151K	0.04%	260
2018 Q4	$322K	Hold	20,900	–	–	0.06%	183
2018 Q3	$450K	Hold	20,900	–	–	0.07%	174
2018 Q2	$508K	Hold	20,900	–	–	0.09%	160
2018 Q1	$357K	Hold	20,900	–	–	0.06%	178
2017 Q4	$396K	Hold	20,900	–	–	0.07%	173
2017 Q3	$368K	Hold	20,900	–	–	0.07%	174
2017 Q2	$694K	Hold	20,900	–	–	0.13%	132
2017 Q1	$671K	Sell	20,900 -200	-0.9%	-$6.83K	0.12%	137
2016 Q4	$765K	Hold	21,100	–	–	0.14%	125
2016 Q3	$971K	Hold	21,100	–	–	0.19%	105
2016 Q2	$1.06M	Hold	21,100	–	–	0.21%	98
2016 Q1	$1.13M	Hold	21,100	–	–	0.23%	96
2015 Q4	$1.39M	Hold	21,100	–	–	0.29%	85
2015 Q3	$1.25M	Hold	21,100	–	–	0.27%	86
2015 Q2	$1.3M	Sell	21,100 -150	-0.7%	-$9.25K	0.26%	89
2015 Q1	$1.32M	Sell	21,250 -140	-0.7%	-$8.14K	0.26%	94
2014 Q4	$1.23M	Hold	21,390	–	–	0.24%	93
2014 Q3	$1.15M	Hold	21,390	–	–	0.24%	89
2014 Q2	$1.17M	Hold	21,390	–	–	0.24%	89
2014 Q1	$1.13M	Hold	21,390	–	–	0.25%	89
2013 Q4	$857K	Buy	21,390 +15,750	+279%	+$620K	0.19%	104
2013 Q3	$213K	Buy	5,640 +140	+3%	+$5.46K	0.05%	206
2013 Q2	$216K	Buy	+5,500	New	+$214K	0.06%	197

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

Osborn Williams & Donohoe's TEVA Position: Q4 2019 in Review

Osborn Williams & Donohoe sold out of Teva Pharmaceuticals (TEVA) in Q4 2019, closing a stake of 33,868 shares — an estimated $233K sold.

Osborn Williams & Donohoe first reported a position in TEVA in Q2 2013 and held it in 26 quarters. The position peaked at $1.39M in Q4 2015. 436 funds tracked by Wall St. Rank hold TEVA as of Q4 2019.

Osborn Williams & Donohoe reported no remaining Teva Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Osborn Williams & Donohoe sold 33,868 Teva Pharmaceuticals shares in Q4 2019, an estimated $233K.
Osborn Williams & Donohoe first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 26 quarters.
Osborn Williams & Donohoe's Teva Pharmaceuticals position peaked at $1.39M in Q4 2015.
436 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2019.

Based on Osborn Williams & Donohoe's 13F filing for Q4 2019, filed 2 Mar 2020.